Skip to content
Veracyte is a leading genomic diagnostics company that is fundamentally improving patient care by resolving diagnostic uncertainty with evidence that is trustworthy and actionable. The company’s products uniquely combine genomic technology, clinical science and machine learning to provide answers that give physicians and patients a clear path forward without risky, costly surgery that is often unnecessary.
Since its founding in 2008, Veracyte has commercialized three genomic tests, which are transforming the diagnosis of thyroid cancer, lung cancer and idiopathic pulmonary fibrosis and collectively target a $2 billion market opportunity. Veracyte is based in South San Francisco, California. Veracyte’s common stock is listed on The NASDAQ Global Market under the symbol VCYT.


Press Releases

Date Title and Summary Additional Formats
Toggle Summary Veracyte Announces Publication Highlighting Afirma GSC’s Ability to Rule Out Cancer in Challenging Thyroid Nodule Subtype
RNA whole-transcriptome and machine learning platform enables genomic test to distinguish benign Hürthle cells, reducing potential for unnecessary surgeries SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Apr. 8, 2019-- Veracyte, Inc . announced today that a new study published online in BMC Systems
Toggle Summary Veracyte to Release First Quarter 2019 Financial Results on April 30, 2019
SOUTH SAN FRANCISCO, Calif. --(BUSINESS WIRE)--Apr. 3, 2019-- Veracyte, Inc. (Nasdaq: VCYT) today announced that it will release its financial results for the first quarter 2019 after the close of market on Tuesday, April 30, 2019 . Company management will host a conference call and webcast to


Date Event Details
Summary Toggle Apr 30, 2019 2:00 PM PDT
Veracyte First Quarter 2019 Financial Results Webcast
Summary Toggle Apr 10, 2019 8:00 AM EDT
18th Annual Needham Healthcare Conference


Title Documents

Corporate Presentation April 2019